Sante Mernaud Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 06-07-2024
- Paid Up Capital ₹ 1.38 Cr
as on 06-07-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.37 Cr
as on 06-07-2024
- Revenue 20.58%
(FY 2020)
- Profit 76.46%
(FY 2020)
- Ebitda 712.91%
(FY 2020)
- Net Worth 0.43%
(FY 2020)
- Total Assets -7.83%
(FY 2020)
About Sante Mernaud Pharmaceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.38 Cr.
The company currently has active open charges totaling ₹1.37 Cr.
Shivabasavesh Hiremath, Shoba Hiremath, Motilal Doddamani, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239KA2006PTC039813
- Company No.
039813
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2006
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sante Mernaud Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shoba Hiremath  | Director | 26-Jun-2006 | Current |
| Shivabasavesh Hiremath | Director | 26-Jun-2006 | Current |
| Motilal Doddamani | Whole-Time Director | 01-Mar-2012 | Current |
| Amogh Hiremath | Director | 19-Dec-2020 | Current |
| Kalennahalli Jagadesha | Director | 10-May-2021 | Current |
Financial Performance and Corporate Structure Insights of Sante Mernaud Pharmaceuticals.
Sante Mernaud Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 20.58% increase. The company also saw a substantial improvement in profitability, with a 76.46% increase in profit. The company's net worth moved up by a moderate rise of 0.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sante Mernaud Pharmaceuticals?
In 2020, Sante Mernaud Pharmaceuticals had a promoter holding of 73.26% and a public holding of 26.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 10 Jul 2007 | ₹0.65 M | Open |
Canara Bank Creation Date: 21 Mar 2007 | ₹1.30 Cr | Open |
How Many Employees Work at Sante Mernaud Pharmaceuticals?
Sante Mernaud Pharmaceuticals has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Nov 18, 2014, Sante Mernaud Pharmaceuticals has raised a total of ₹ 6.15 Cr, with the most recent deal valued at ₹ 2 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
